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Abstract: Consumption of whole grains have been associated with reduced risk of chronic diseases in
many observational studies; yet, results of intervention studies are mixed. We aimed to use evidence
mapping to capture the methodological and reporting variability in whole grain intervention studies
that may contribute to this inconsistency. We conducted a reproducible search in OVID Medline for
whole grain human intervention studies (published 1946 to February 2018). After screening based on
a priori criteria, we identified 202 publications describing a total of 213 unique trials. Over half (55%)
were acute trials, lasting ≤1 day, 30% were moderate duration studies (up to 6 weeks) and 15% were
of longer duration (more than 6 weeks). The majority of acute trials (75%) examined measures of
glycaemia and/or insulinemia, while most of the longer trials included measures of cardiometabolic
health (71%), appetite/satiety (57%) and weight/adiposity (56%). Among the moderate and long
duration trials, there was a wide range of how whole grains were described but only 10 publications
referenced an established definition. Only 55% of trials reported the actual amount of whole grains
(in grams or servings), while 36% reported the amount of food/product and 9% did not report a dose
at all. Of the interventions that provided a mixture of whole grains, less than half (46%) reported
the distribution of the different grain types. Reporting of subject compliance also varied and only
22% used independent biomarkers of whole grain intake. This evidence map highlights the need
to standardize both study protocols and reporting practices to support effective synthesis of study
results and provide a stronger foundation to better inform nutrition scientists and public health policy.
Keywords: whole grain; evidence map; intervention; reporting practices
1. Introduction
Whole grain foods have long been promoted as part of a healthy diet and since 2000, specific
whole grain recommendations have been included in the Dietary Guidelines for Americans (DGA) [1].
The most recent 2015 DGA recommends consuming 6 ounce-equivalents of grains per day (based
on a 2000 kcal diet) and that at least half of this amount should be whole grain [2], while some
Nordic countries recommend 75 g whole grain per 10 MJ of energy [3]. While the majority of
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prospective studies has found that consumption of whole grains is associated with health benefits,
including reduced risk of cardiovascular disease (CVD), obesity, diabetes and all-cause mortality [4–7],
evidence of health benefits from intervention studies on obesity and cardiometabolic risk factors
is less consistent. Variation in study design and diet intervention, including the type of grain(s)
provided, dose, duration and background diet of the intervention makes it difficult to compare and
synthesize the conclusions drawn from these studies. Furthermore, universal consensus in defining
whole grain and especially what constitutes a whole grain food is lacking [8]. Definitions vary by
different organizations, particularly for whole grain food products [9,10]. In 1999, AACCI (formerly the
American Association of Cereal Chemists (AACC) International) released a definition stating, “Whole
grains shall consist of the intact, ground, cracked, or flaked caryopsis, whose principal anatomical
components—the starchy endosperm, germ and bran—are present in the same relative proportions
as they exist in the intact caryopsis” [11]. This definition captures whole grain ingredients, such as
flours and intact grains but does not define whole grain food products. The AACCI published that a
whole grain food product should have ≥8 g of whole grains for every 30 g of product (i.e., the typical
serving of a cereal product) [12], while the USDA requires food products have ≥8 g (dry weight)
whole grains per reference amount customarily consumed and ≥51% of the grain ingredients must be
whole grain [13]. In 2010, the Healthgrain Forum, a non-profit organization of academics and industry
interested in cereals and health, issued a similar whole grain definition as the AACCI; however,
this definition specifies “small losses of components, that is, less than 2% of the grain or 10% of the
bran that occurs through processing methods are allowed” to account for what happens at most flour
mills. More recently, the Healthgrain Forum has defined whole-grain foods as a food that “contains
>30% whole grain ingredients in the overall product and contains more whole grain than refined grain
ingredients, both on a dry weight basis,” and recommends that only foods that meet healthy eating
criteria be labelled as “whole grain” [10]. Both the AACCI and Healthgrain definitions include the
cereal grasses and the pseudocereals (amaranth, buckwheat, quinoa and wild rice). The 2015 DGA
describes whole grains in terms of ounce-equivalents, with 1 ounce-equivalent of 100 percent whole
grain food having 16 g of whole grains (based on the minimum whole grain content of a 1 ounce
slice of bread that would meet the U.S. Food and Drug Administration (FDA) health claim criteria
of 51% or more whole grain) [2]. Other definitions and recommendations use grams of whole grain.
The lack of consistency and limitations in defining whole grain foods lends itself to confusion and
creates difficulty in standardizing diet interventions and comparing results across intervention studies.
Recognizing the need to improve study design reporting in research in the whole-grain field, Ross
and colleagues [14] highlighted several recommendations for reporting whole grain intake in both
observational and intervention studies. These recommendations included the following: (i) report
the grams of whole grain consumed/provided rather than the amount of whole grain food/product
and account for water content; (ii) report which definition of whole grain is being used; (iii) report
the proportion of different grains consumed/provided and not just the total amount of whole grains;
(iv) describe the structure and processing of the grains; (v) report added bran or germ separately
(a methodological issue encountered in observational studies); (vi) use a refined grain control instead
of “usual diet”; (vii) use biomarkers of whole grain intake whenever possible.
We evaluated the differences in study design and reporting practices of studies, using the
above criteria as guidelines, by creating an evidence map. Evidence mapping is a method by which
scientific evidence on an expansive or complex topic is identified, organized and summarized [15].
Evidence mapping involves the collection of population, intervention, comparator and outcome (PICO)
information in order to characterize the existing research landscape in a broad area. It is similar to the
first steps in a systematic review; however, in contrast to systematic reviews, evidence mapping does
not include data on study results or provide in-depth risk of bias evaluations. Instead, the focus is
more on capturing the history and trajectory of the topic area, as well as an assessment of the variation
in methodology, such as in the present study. One appreciable difference between evidence mapping
and systematic reviews is that evidence mapping provides a larger, more comprehensive scope of the
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research area than is usually addressed in a systematic review and the goal is to produce an updatable
descriptive map that can be used for different purposes. Evidence mapping has been used to promote
evidence-based decision making [16–18] and this method has previously been employed to summarize
research on nutrition topics such as sugar-sweetened beverages [19], dietary fiber [20], low-calorie
sweeteners [15] and trans fatty acids [21].
The purpose of conducting an evidence map is to summarize research in the field, potentially
providing researchers with insight about research gaps or trends that may facilitate new work in
the field. The growing body of research on whole grains, the variation in outcomes in intervention
studies, as well as the many health outcomes being measured with respect to whole grain intake,
makes this an ideal area for using evidence mapping methodology. Therefore, the aim of this project
was to (i) summarize the current body of literature on whole grain intervention studies and health
and (ii) apply evidence mapping methodology to evaluate variation in study design and variation in
reporting practices among longer-duration whole grain studies.
2. Materials and Methods
Evidence mapping consists of three main steps: (i) clearly defining a topic area of interest;
(2) systematically searching and screening relevant studies based on pre-defined criteria; and
(3) extracting and reporting on study characteristics or other questions of interest, creating a “map” of
available evidence [15–17].
2.1. Search Strategy
We aimed to collect all published intervention studies examining the effect of whole grain
consumption on health. We conducted a systematic, reproducible search in OVID Medline for whole
grain intervention studies using a broad list of whole grain key terms. The search extended from
inception of the Medline database (1946) to February 2018. The search was restricted to human
intervention studies published in English. Observational studies, case reports, bibliographies, letters,
editorials and reviews were specifically excluded. For the list of search terms used see Table S1.
We used the multi-purpose search feature in OVID to search all fields including title, abstract, subject
heading words and keyword heading words.
2.2. Selection Criteria
Results of our search were screened in two phases based on a priori selection criteria. For phase 1,
we used the free, open source platform, ABSTRAKR, developed by the Evidence-Based Practice Center
at Brown University [22], to conduct an initial screening of abstracts identified in Medline. This phase
used a low-threshold of inclusion in an attempt to include all potentially relevant publications. To be
included at this phase, studies had to be (i) intervention studies; (ii) conducted in human subjects;
and (iii) published in English. Exclusion criteria at this phase were: (i) animal studies; (ii) in-vitro
studies; (iii) reviews, bibliographies, case reports, letters, or any other non-intervention study; (iv) no
inclusion of whole grains in the intervention. Studies for which abstracts were not found or where
inclusion/exclusion was unclear were moved forward for secondary screening.
For secondary screening, full-text manuscripts were obtained. During this phase, additional
exclusion criteria were applied to better restrict the results to whole grain interventions most relevant
to the general population. These exclusion criteria included the following: (i) the intervention did not
allow the effect of whole grain to be isolated (including whole grain products with added bran); (ii) the
intervention was only an isolated component of whole grain (e.g., bran, germ, fiber); (iii) subjects were
following a gluten-free diet; (iv) subjects were <3 years old (purpose was complementary feeding
practices with enriched whole grains on nutritional status or to assess digestibility of grain product
in infants); (v) the study was specific to oral rehydration or refeeding therapies; (vi) subjects were
pregnant or breastfeeding women; (vii) in vitro studies; (viii) animal studies. Reasons for exclusion
during this phase were documented.
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2.3. Data Abstraction and Analysis
An Excel spreadsheet was used to collate data from eligible publications. Information collected
included study design, subject characteristics, details of whole grain interventions and controls
(including dose, duration, processing and form) and reported outcomes (but not specific results).
For studies that included more than one whole grain intervention group, a new record was created
for each intervention. Some publications included multiple, distinct studies. These were entered
as separate studies. To synthesize these data, studies were mapped descriptively by study design,
intervention (whole grain type), and/or outcomes. These data can be used to create clusters of evidence
in specific areas of focus.
Whole grain intervention treatments were extracted as described in the publications. We then
grouped interventions by grain type (e.g., wheat, barley, rye). If the intervention included more
than one type of grain given simultaneously (such as multigrain products or mixed whole grain
diet interventions with commercially available products), or if the publication did not describe the
specific type(s) of grains (e.g., fiber-rich whole-grains), these interventions were grouped under the
general category “mixed whole grain (WG).” Similarly, control treatments were extracted as described
in publications and were then grouped as refined grain, usual diet, matched (same intervention
as treatment but without any added whole grain), other (including glucose, bran and unspecified
controls), or no control arm.
We categorized studies by study duration as acute (<1 day), moderate duration (1 day to
6 weeks), or long duration (>6 weeks). We then categorized studies by design (randomized controlled
parallel, randomized controlled crossover, or other designs), sample size, subject characteristics and
region. We grouped outcome measures into the following broad categories: glycaemia/insulinemia
(e.g., fasting and postprandial glucose and insulin, HbA1c, glucose turnover), appetite/satiety
(e.g., hunger, fullness, energy intake, ghrelin), cardiometabolic health (e.g., blood pressure, lipids,
inflammatory markers, oxidative markers), weight/adiposity (e.g., body weight, body mass index,
waist-to-hip ratio, adipose tissue), gastrointestinal (GI) function/microbiota (e.g., transit time, laxation,
fecal pH, bacterial composition, short-chain fatty acids, breath hydrogen), exercise/physical activity
(e.g., resting metabolic rate, energy expenditure, physical activity, exercise intensity) and micronutrient
status (e.g., blood and/or urine concentrations of sodium, potassium, magnesium, iron, zinc).
In addition to highlighting variability in study design, we also evaluated the variability in
reporting practices in the moderate and long duration trials. For this purpose, we examined what
types of whole grain definitions were used or referenced, how whole grain type and dose was reported
and whether whole grain biomarkers were used for compliance.
3. Results
3.1. Literature Search and Screening
The results of the systematic Medline search for published intervention studies examining the
effect of consumption of whole grains (1946 to February 2018) are presented in Figure 1. The initial
search identified 1709 publications of which 1121 were excluded during abstract-level screening and
an additional 386 were excluded during full-text screening. A total of 202 eligible publications were
identified; however, because some of these publications described multiple unique trials, data was
extracted from 213 trials.
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Figure 1. Flow diagram of literature search and screening results.
3.2. Study Design Characteristics
Trials that lasted ≤1 day were labelled “acute” trials (n = 118 trials among 109 publications),
while studies of moderate (>1 day to 6 weeks, n = 63 trials) and long (>6 weeks, n = 32 trials) durations
are referred to as “longer duration” trials (n = 95 trials among 95 publications). Two publications
detailed both acute and longer duration trials [23,24]. The number of trials by duration, with each
major outcome category and the type of grain interventions, are summarized in Figure 2. The majority
of the acute trials (75%, n = 88) focused on glycaemia and/or insulinemia outcomes, while the major
outcomes in the longer (moderate and long) duration trials were cardiometabolic health measures
(71%, n = 67), measures of appetite/satiety (57%, n = 54) and measures of weight/adiposity (56%,
n = 53).
Table 1 summarizes the study design characteristics of all trials categorized by study duration
(acute, moderate, long). Among the acute trials, the most common design was a randomized, controlled,
crossover trial (n = 100, 85%). Only one trial used a randomized, controlled, parallel trial design and a
number of studies did not specify randomization (n = 16), or used a single arm study design (n = 1).
Most acute trials had a sample size of less than 25 (n = 97, 82%) and 33% had 10 or fewer subjects
(n = 39). The majority of studies recruited healthy (n = 79, 67%) adults (≥18 years) (n = 115, 97%).
Only 38% were metabolically-at-risk, that is, had type 2 diabetes (15%), were overweight or obese
(16%), or had metabolic syndrome or at least one criteria of metabolic syndrome (hyperglycemia,
hypertension, or hyperlipidemia) (7%).
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trial duration. 1 Acute: <1 day; 2 Moderate duration: >1 day to 6 eeks; 3 onger duration: >6 weeks;
4 Glycaemia/Insulinemia e.g., fasting and postprandial glucose i sulin, HbA1c, glucose turnover;
5 Appetite/satiety e.g., hunger, fullness, energy intake, lin; 6 Cardiometabolic health e.g., blood
pressure, lipids, inflammatory markers, oxidative markers; 7 GI function/microbiota e.g., transit
time, laxation, fecal pH, bacterial composition, short-chain fatty acids, breath hydrogen; 8 Exercise
Performance/Energy balance e.g., resting metabolic rate, energy expenditure, physical activity, exercise
intensity, stool energy density; 9 Micronutrient Status e.g., concentrations of sodium, potassium,
magnesium, iron, zinc, minerals; 10 Weight/Adiposity e.g., body weight, BMI, body fat/adipose tissue,
waist circumference, lean body mass; 11 Mixed whole grain (WG) group includes combinations of 2 or
more whole grains, whole grain diets and unspecified “whole grain” foods (ex: whole grain bread).
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Table 1. Study design characteristics of whole grain intervention trials in humans, organized by
trial duration.
Characteristic Acute Moderate (>1 Day–6 Weeks) Long (>6 Weeks)
Total RCT Other 1 Total RTC Other 2 Total RTC Other 3
Number of trials, n 118 101 17 63 57 6 32 31 1
Parallel, n (%) - 1 (1) - - 20 (35) - - 26 (84) -
Crossover, n (%) - 100 (99) - - 37 (65) - - 1 (3) -
Duration, n (%)
≤ 1 day 118 (100) 101 (100) 17 (100) - - - - - -
< 1 week - - - 10 (16) 7 (12) 3 (50) - - -
1 to 6 weeks - - - 53 (84) 50 (88) 3 (50) - - -
6 to 12 weeks - - - - - - 25 (78) 24 (77) 1 (100)
>12 weeks - - - - - - 7 (22) 7 (23) 0 (0)
Sample size, n (%)
≤10 39 (33) 29 (29) 10 (59) 4 (6) 2 (4) 2 (33) 0 (0) 0 (0) 0 (0)
11–25 58 (49) 54 (53) 4 (24) 27 (43) 23 (40) 4 (67) 4 (13) 4 (13) 0 (0)
26–50 16 (14) 15 (15) 1 (6) 18 (29) 18 (32) 0 (0) 9 (28) 8 (26) 1 (100)
>50 5 (4) 3 (3) 2 (12) 14 (22) 14 (25) 0 (0) 19 (59) 19 (61) 0 (0)
Age group, n (%)
Adults (≥18 year) 115 (97) 98 (97) 17 (100) 60 (95) 54 (95) 6 (100) 31 (97) 31 (100) 0 (0)
Adolescents (12–17) 0 (0) 0 (0) 0 (0) 2 (3) 2 (4) 0 (0) 0 (0) 0 (0) 0 (0)
Children (3–11 year) 2 (2) 2 (2) 0 (0) 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
NR 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 1 (100)
Sex, mean % male± SD 54 ± 27 55 ± 26 50 ± 32 44 ± 25 43 ± 23 49 ± 42 42 ± 21 40 ± 18 100 ± 0
Baseline health, n (%)
Healthy 79 (67) 67 (66) 12 (71) 30 (48) 26 (46) 4 (67) 4 (13) 4 (13) 0 (0)
Overweight/Obese 19 (16) 18 (18) 1 (6) 19 (30) 18 (32) 1 (17) 19 (59) 18 (58) 1 (100)
T1DM 2 (2) 1 (1) 1 (6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
T2DM 18 (15) 15 (15) 3 (18) 5 (8) 3 (5) 2 (33) 4 (12) 4 (13) 0 (0)
MetS (≥1 criteria) 4 8 (7) 7 (7) 1 (6) 20 (32) 19 (33) 1 (17) 15 (47) 14 (45) 1 (100)
Digestive Issues 3 (3) 2 (2) 1 (6) 3 (5) 3 (5) 0 (0) 1 (3) 1 (3) 0 (0)
Region, n (%)
Europe 61 (52) 54 (53) 7 (41) 28 (44) 24 (42) 4 (67) 17 (53) 17 (55) 0 (0)
North America 36 (31) 33 (33) 3 (18) 21 (33) 20 (35) 1 (17) 8 (25) 8 (26) 0 (0)
Asia 12 (10) 5 (5) 7 (41) 10 (16) 9 (16) 1 (17) 6 (19) 5 (16) 1 (100)
Australia 6 (5) 6 (6) 0 (0) 3 (5) 3 (5) 0 (0) 0 (0) 0 (0) 0 (0)
Africa 2 (2) 2 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
South America 0 (0) 0 (0) 0 (0) 1 (2) 1 (2) 0 (0) 0 (0) 0 (0) 0 (0)
Multiple 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 1 (3) 0 (0)
Controls 5, n (%)
Refined grain 98 (74) 86 (75) 12 (67) 47 (71) 44 (75) 3 (43) 22 (69) 21 (68) 1 (100)
Usual diet 0 (0) 0 (0) 0 (0) 2 (3) 1 (2) 1 (14) 5 (16) 5 (16) 0 (0)
Matched, no WG 6 4 (3) 3 (3) 1 (6) 4 (6) 4 (7) 0 (0) 2 (6) 2 (6) 0 (0)
Other 7/unspecified 21 (16) 17 (15) 4 (22) 6 (9) 6 (10) 0 (0) 3 (9) 3 (10) 0 (0)
Crossover of WG only 8 10 (8) 9 (8) 1 (6) 4 (6) 4 (7) 0 (0) 0 (0) 0 (0) 0 (0)
No control arm 0 (0) 0 (0) 0 (0) 3 (5) 0 (0) 3 (43) 0 (0) 0 (0) 0 (0)
RCT = randomized controlled trial; NR = not reported; SD = standard deviation; MetS = metabolic syndrome;
WG = whole grain; 1–3 Other study designs include: 1 crossover, unspecified randomization (n = 14); parallel,
unspecified randomization (n = 2); single arm (n = 1); 2 single arm with no control (n = 3) and single arm, with
control period (n = 3); 3 unspecified randomization, crossover (n = 1); 4 Have metabolic syndrome or at least one
criteria of metabolic syndrome (hyperlipidemia, hypertension, or hyperglycemia); 5 Note that some trials included
more than one control arm (total control arms for acute, moderate and long duration trials are n = 133, 66 and 32,
respectively); 6 Identical intervention as treatment arm(s) except without whole grain ingredient(s) (e.g., “controlled
diet alone,” “yogurt without oats”); 7 Other controls include bran, sucrose and unspecified controls (ex: “placebo”);
8 Crossover studies of different whole grain types, without a non-whole grain arm.
Moderate duration trials were also mostly RCTs with a cross-over design (n = 37, 59%), while
long duration trials mostly implemented RCT parallel designs (n = 26, 81%). Of the other designs
used, six trials were single arm (moderate duration) and one trial did not specify randomization (long
duration). Moderate duration studies ranged from 2 days (n = 1 trial) to 6 weeks (n = 23 trials)
(interquartile range (IQR) = 3 weeks). Long duration studies ranged from 8 weeks to 2 years
(IQR = 3 weeks) but only 7 trials were > 12 weeks. Sample size ranged from 5 to 266 participants (mean
± SD = 45.7 ± 54.4) for the moderate duration trials and from 18 to 266 participants (mean ± SD =
92.3 ± 77.9) for the long duration trials. Similar to the acute studies, most of the longer duration trials
were in adults (n = 91, 96%) but of the moderate duration 2 trials were conducted in adolescents (aged
12–17 years) and one in children aged 3–11 years. Compared to the acute studies, subjects recruited in
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the longer duration trials were less likely to be healthy; 40% were overweight or obese (n = 38) and
46% had other risk factors of the metabolic syndrome (n = 44).
Figure 3 is a weighted scatter plot that displays the trials by the different grain types used in the
interventions and the outcomes examined. Each bubble represents a single publication within each
grain-by-outcome category, the size corresponds to the study sample size and the color corresponds to
the duration of the trial (acute, moderate, long). Most trials administered a wheat-based intervention
(21%), closely followed by mixed whole grain interventions (19%), oats (18%), rye (15%), barley (8%)
and brown rice (8%). With respect to whole-grain diet interventions (grouped in mixed WG) (n = 39),
the vast majority of the inventions provided study participants with the choice of commercially
available whole-grain products (data not shown). The study design characteristics were similar across
the top grain types, but, notably, none of the rye trials were of >6 weeks in duration or had larger
sample sizes. In fact, only four grain types (mixed whole grains, wheat, oat and brown rice) were used
in the long (>6 weeks) trials. The moderate duration trials additionally included rye, barley, buckwheat,
sorghum and quinoa and just a few acute studies examined other types of grain (whole corn, millet,
bulger, amaranth, teff and triticale).
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and brown rice) were used in the long (>6 weeks) trials. The moderate duration trials additionally 
included rye, barley, buckwheat, sorghum and quinoa and just a few acute studies examined other 
types of grain (whole corn, millet, bulger, amaranth, teff and triticale).  
 
Figure 3. 1 Each bubble represents a single publication within each grain by outcome category and
the size corresponds to the study sample size; position of bubbles is random within each cell; trial
bubbles are duplicated between outcome or grain categories when >1 outcome of grain type was
studied; 1 Mixed Whole Grain (WG) group includes combinations of 2 or more WGs, WG diets and
unspecified WG foods (ex: WG bread); 2 Other outcomes include exercise performance, micronutrient
status, clinical blood and urine measures and other metabolites.
3.3. Reporting Practices
In Table 2, reporting practices based on recommendations from Ross et al., [14] for the moderate
and long-term interventions were examined. The whole grain interventions were described in varying
degrees of detail but most publications (n = 61, 73%) did not specify a definition for whole grain
product or whole grain food. When a definition was provided, only 12% (n = 10) referenced an
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established definition, which included the American Association of Cereal Chemists (n = 5) [11,12],
Proceedings of the Nutrition Society (n = 1) [25], Dietary Guidelines for Americans (n = 2) [26,27] and
HealthGrain Forum (n = 4) [28]. The rest provided various general descriptions of whole grain or
whole grain food (n = 12). Specific definitions/descriptions are listed in Table S2. When reporting the
whole grain dose administered, the actual amount of whole grain provided was not always clear: 55%
(n = 52) of longer duration trials reported grams or servings of whole grain but 36% (n = 34) reported
the grams or servings of whole grain food/product (thus providing no actual quantifiable amount of
whole grain) and 9% (n = 9) failed to report a dose at all. Further, among the longer interventions that
provided a variety of whole grains (either as a part of a diet or a multi-grain food/product) (n = 39),
less than half (46%, n = 18) reported the distribution of the different grains types. Additionally, while
73% used diet records or questionnaires to measure compliance, only 22% (n = 26) of longer duration
trials used biomarkers of whole grain intake. A few (n = 14, 15%) used food weighing, wrappers,
or direct observation and 20% (n = 19) did not report on any compliance measures.
Table 2. Reporting practice in moderate (>1 day to 6 weeks) and long (>6 weeks) duration whole grain
intervention trials in humans.
Reporting Criteria n (%)
Reporting of dose
Amount of grain 52 (55)
Amount of food/product 34 (36)
Not reported 1 9 (9)
Reported a definition of whole grain
Referenced established definition 2 10 (12)
Described WG or WG food 12 (14)
Not reported 61 (73)
Reported distribution of grain types 3 18 (46)
Control
Refined grain 69 (70)
Usual diet 7 (7)
Other 4 22 (22)
Adherence 5
Questionnaires/Records 69 (73)
Food weighing or observation 14 (15)
Biomarkers 26 (22)
Not reported 19 (20)
1 Either no dose reported (n = 6) or the dose was not clearly reported as amount of grain versus amount of food
(n = 3); 2 Among studies published after 1999 (n = 83), the year of the first published definition by AACCI; AACCI
1999 (n = 2), AACCI 2005 (n = 1), AACCI 2013 (n = 2); Dietary Guidelines for Americans (DGA) 2005 (n = 1),
DGA 2010 (n = 1); HealthGrain Forum 2014 (n = 4); Proceedings of Nutrition Society 2006 (n = 1); note that two
publications referenced more than one established definition; 3 Among interventions that provided a variety of WGs
simultaneously n = 39; 4 Other controls included bran (n = 4), sucrose (n = 1), unspecified low-fiber cereal (n = 1),
“placebo” (n = 1), standard dietary advice for Type 2 Diabetes (n = 2), matched intervention without addition of WG
(n = 6), cross-over of whole grain only (n = 4), or no control arm (n = 3); 5 Note that some studies used more than
one category of adherence measure and therefore are counted in more than one category.
4. Discussion
Until the last 10 years, there was little research on whole grains, with fewer than 6 whole grain
intervention studies published per year prior to 2008 (Figure S1). With the rapid increase in studies,
it is important to reflect on the current state and trajectory of the existing evidence. Using evidence
mapping methodology, we are able to evaluate variation in study design and reporting practices among
whole grain intervention studies. This evidence map consisted of 202 publications that described
213 unique whole grain intervention trials in humans. Acute trials (n = 118) consisted of a single meal
or individual whole grain food (e.g., oats) intervention, with follow-up lasting up to 24 hours. These
acute studies focused primarily on the postprandial effects of whole grain consumption, especially
measures of glucose response and appetite/satiety. Moderate and longer duration trials (n = 95),
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in which whole grain interventions were given from 2 days to 2 years, captured dietary interventions
that included a range of whole grain foods and whole-grain mixed diets (mainly based on wheat).
The most frequent outcomes examined in the moderate and long duration studies included markers of
cardiometabolic health (e.g., changes in lipids, markers of inflammation and oxidative stress, blood
pressure) and changes in weight or adiposity, outcomes that have gained more focus particularly in
the past 10 years (Figure S2). Gastrointestinal function and microbiota related outcomes have also
gained more attention recently. With regard to grain type, whole grain wheat and oats have remained
among the most frequently studied grain types among both acute and non-acute studies over time,
but other grain types, including rye, brown rice, whole corn and buckwheat, have really only grown
in interest over the last 10 years (Figure S3). Additionally, there has been a notable increase in mixed
whole grain diet interventions since the early 2000s.
In terms of study design and subject characteristics, nearly all the acute trials used a cross-over
design in healthy subjects, while a larger proportion of the non-acute trials utilized parallel arms and
were more likely to include metabolically at-risk subjects. Most subjects in these trials were overweight
or obese, had metabolic syndrome, or had other metabolic risk factors (hypertension, hyperlipidemia,
hyperglycemia). However, there are far fewer trials of moderate and long duration, and, therefore,
the literature may be unbalanced toward short studies among healthy subjects.
Another area of inconsistency in whole-grain research is the units used to report the whole grain
quantity, or dose. Ross and colleagues [14] recommend that researchers report the gram amount of
whole grains provided, rather than the amount of the whole grain food or product. In our evidence
map, we found that while the majority (53%) of longer duration trials provided grams of whole grain
(such as grams of barley kernels, grams of wheat flour, etc.), a large proportion (41%) instead reported
the gram weight of the whole grain food (such as rye bread or muffin) or whole grain product (such as
ready to eat breakfast cereal, packaged snack bars, etc.). Given the variability and limitations in
defining a whole grain food (both among research publications and food industry) [10], the actual
grams of whole grain ingredients delivered in the intervention could vary considerably because of
the variation in the amount of whole grains in whole grain products, particularly when many whole
grain products contain a mixture of whole and refined grain. This variability creates a challenge
for researchers when attempting to estimate absolute whole grain intake in both observational and
intervention studies [9,14] and confounds efforts to relate the amount of whole grains eaten to possible
effects on disease risk. Similarly, the use of ounce equivalence in some studies, in-line with USDA
dietary recommendations, also prevents accurate estimation of whole grain intake for the same reason
that one ounce equivalent of whole grain food may be anywhere from 16 to 28 g.
Over 70% of moderate and long duration publications did not specify a definition of whole grain
or whole grain food. It is important to note that many of these studies may have provided a single
intact whole grain intervention, such as oats, and therefore may not have found it necessary to specify
a definition of whole grain. However, when a whole grain is incorporated into foods (and diets) it
becomes more important to specify these definitions. Although it seems that more recent studies are
more likely to include a definition, the lack of a standard definition of whole-grain foods remains a
major challenge for researchers, especially for comparing between different studies.
Interventions using a mixture of different types of whole grains, either in food products or overall
diets, have become more prevalent over the past 5–10 years, particularly among non-acute trials
(n = 39 trials). For example, some studies instructed subjects to consume a certain amount of whole
grains per day, with a choice from a variety of products [29–32]. In such cases, Ross et al., have
discussed the need to describe the proportion of each specific grain consumed/provided [14]. In our
evidence map, we found that 54% of these mixed-grain intervention studies did not provide details
on individual grain types. Different grains have different compositions, including the types and
concentrations of fibers and phytochemicals [33–35] and, therefore, may have different physiologic
effects. For example, there is some evidence that oats and rye may be more beneficial to cardiovascular
health than whole grain wheat [36]. While it is important to observe the effects of mixed-grain diets,
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as most people consume multiple types of grains, authors should report the specific types and relative
amounts of individual grains.
There was also concern in the reporting of intervention compliance. Most studies used
questionnaires or diaries but these are open to bias. One study using a biomarker found that in a whole
grain intervention group, only approximately 40% of the subjects complied with the target amount of
whole grain [37]. We identified 26 moderate or long duration trials that incorporated an independent
biomarker of whole grain intake. These biomarkers included blood or urine concentrations of
enterolactones [38–43] and/or alkylresorcinols [31,40,41,44–52]. Use of reliable biomarkers of intake
strengthens a study’s design by removing potential reporting bias associated with self-reported
compliance. It should be noted that there are some limitations to using biomarkers; alkylresorcinols,
for example, are only found in wheat, rye, and, to a lesser extent, barley, while enterolactones
are confounded by antibiotic intake and are increased with many plant foods [53]. In addition,
most biomarkers have short half-lives, which means they generally only reflect recent intake [44],
though cereal foods are usually eaten on a daily basis so this is less of a limiting factor. The issue of
compliance is increasingly important, as we noted that more studies are moving away from completely
controlled diet interentions, which can be expensive, and are instead relying on subjects to incorporate
the intervention food(s) into their usual or normal diet.
The changing landscape of nutrition research makes whole grain research challenging to
summarize and our evidence map highlights gaps in the research and study design considerations
for future work. While there are many meta-analyses that focus on whole grains [4,54–56], there are
fewer that focus on the health effects of specific grains other than oats [57–60]. However, we found
that a large proportion of intervention studies administer whole wheat (21%) and a number of studies
also focus on rye (15%), barley (8%) or brown rice (8%). This is similar to findings in a systematic
review by Cho et al., stating that, “most RTCs and meta-analyses of RCTs did not capture the impact
of major whole grains, such as wheat and corn, consumed in the United States” [61]. Therefore, more
meta-analyses on these specific grains may be beneficial, especially in influencing policy and/or
dietary recommendations [62]. Research on the health benefits of whole-grains should continue to
grow with a particular focus on intervention studies examining less studied whole-grains such as
millet, sorghum, quinoa, bulgur, amaranth, teff and triticale.
Evidence mapping is a dynamic method that allows for the ongoing addition of newly published
literature. Thus, it allows us to capture the evolution of study design reporting practices in the
whole-grain field. One limitation of this evidence map is that it does not include any data on the
effect of whole grains on outcomes. However, systematically updating our whole grain database and
corresponding evidence map will help to identify major gaps and/or areas with sufficient data on
health benefits and, thus, provide the justification needed to move forward with a systematic review
or meta-analysis. Detailed reporting of whole grain interventions is critical for facilitating summaries
of the evidence, through systematic reviews, meta-analyses, or evidence mapping. Finally, researchers
pursuing future work in the field must focus on standardizing whole grain reporting practices and
study methodologies. Ensuring these best practices will allow for effective synthesis of study results in
meta-analyses and, thereby, provide a stronger foundation to better inform nutrition scientists and
public health policy.
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